GBA Presents: RADIO SAVANT-!

From Oct 2021-

Summary
  • The company is developing a more efficient, bi-directional power switch technology based on their innovative B-TRAN technology.
  • B-TRAN brings important advantages in terms of energy efficiency gains, reduced losses, bi-directionality and reduced bill of materials and heat production.
  • B-TRAN is well protected by 65 patents and 23 pending patents.
  • The company is engaged in developing power switches and circuit breakers to customer specification in an iterative process, producing increasing customer interest.
  • Commercialization is at least a year away, but the company has cash to continue multiple years.
That times out to Now-!
 
Last coverage 5/23

Ideal Power price target lowered to $18 from $28 at Benchmark 05/23/22 IPWR Benchmark analyst David Williams lowered the firm's price target on Ideal Power to $18 from $28 to reflect multiple compression across the semi complex and a "less optimistic macro outlook," but keeps a Speculative Buy rating on the shares, arguing that company "continues its steady cadence of progress toward B-Tran commercialization and developing a strong pipeline of potential customers." Financial results were in line with his expectations and he remains encouraged by the strong product interest developing across an increasingly broad base of applications and diversified set of end markets, Williams added.
 
GBA INITIATES COVERAGE- $10.25





a15ce0d2ab78075dfb794dc12cedbedb
 
ARKK is for big time losers Van you just buy Ginko Bioworks!
Seems like that's all she does. Ask yourself do I want to be surrounded by these wacky types?

Innovators..... Talk about famous last words.
 
stonedinvestor said:
STOCK OF THE DAY- Axsome
This was up 11% yest! Because a competitor tripped up-
Always a good set up.

c3df7230-34e8-11eb-9965-9e24dd439abe

Relmada Tanks After 'Paradoxical Results' Undermine Depression Drug; Axsome Surges

Axsome Therapeutics, Inc. (AXSM)
NasdaqGM - NasdaqGM Real Time Price.
46.21+4.78(+11.54%)
At close: October 13 04:00PM EDT
47.20+0.99(+2.14%)<----------------
Pre-Market:09:06AM EDT

Relmada failure 'direct net positive' for Axsome, says Mizuho 06:48 AXSM, RLMD Shares of Axsome Therapeutics (AXSM) closed up 12% yesterday following the announcement of negative Phase 3 data for REL-1017, a novel NMDA receptor antagonist being developed by Relmada Therapeutics (RLMD) for the treatment of major depressive disorder, Mizuho analyst Graig Suvannavejh tells investors in a research note. The negative outcome for Relmada is a "direct net positive" for Axsome, says the analyst. He notes that while Axsome has yet to launch Auvelity, REL-1017 has been viewed as a meaningful near-term competitor in an "already crowded" major depressive disorder landscape. He believes the he negative Phase 3 data for REL-1017 comes as a "welcome relief with respect to Auvelity's near-term prospects." Suvannavejh keeps a Buy rating on Axsome with a $76 price target.
More...





Get Ready- $44.25-$44.65 Entry))))))))

Axsome Therapeutics, Inc. (AXSM)
NasdaqGM - NasdaqGM Real Time Price.
45.33-0.88(-1.90%)
As of 10:21AM EDT
 
stonedinvestor said:
I think We Hit a Home Run here look at page... damn it I forgot... It talks about the uses..
just read the whole damn slide show... This is potentially LARge Oh I remember! it talks about lowering the number of power devices from 4 to 1 for EV to house... read it!

https://seekingalpha.com/article/4535955-ideal-power-ipwr-investor-presentation-slideshow
More...
:rolleyes:
It has nothing to do with using an EV to power your house dumb-dumb.
It's internal stuff, it saves power, allegedly. You need to be able to switch between ac and dc in many internal components, and each time you do, there's a power loss. If they cut the drop by 4:1, it would be a big deal. But it has nothing to do with powering your house. :D:banghead::banghead:

Just buy a Generac like the rest of us Stoney.

It is worth watching though. :thumbsup:
 
Hummmmmmm.

This is no layup. Conflicting views- I'm on the Guggenheim side-

Axsome shares could react positively to Relmada trial failure, says BofA 09:18 AXSM, RLMD After Relmada (RLMD) reported a failed Phase 3 MDD monotherapy trial for its REL-1017, BofA analyst Jason Gerberry noted this was a potential competitor to Axsome's (AXSM) recently approved Auvelity so he would "not be surprised" to see Axsome shares trade with some strength as he would expect investors to heavily discount the competitive threat based on the mono trial miss despite Relmada still having data pending for two studies investigating 1017 as an adjunctive treatment. However, he added that Axsome consensus forecasts for U.S. Auvelity sales in MDD "do not appear to reflect a disruptive and direct" in-class competitive threat and he maintains an Underperform rating on Axsome, mainly due to what he sees as Auvelity commercial risk ahead of the Q4 launch.

Show Related Items >> Axsome Therapeutics price target raised to $72 from $64 at Guggenheim 07:45 AXSM, JAZZ Guggenheim analyst Yatin Suneja raised the firm's price target on Axsome Therapeutics (AXSM) to $72 from $64 and keeps a Buy rating on the shares. Axsome completed its acquisition of Sunosi from Jazz Pharmaceuticals (JAZZ) on May 9 and Q3 will be the company's first full quarter recording U.S. revenues of the product and Auvelity for MDD was approved in August, noted Suneja, who has updated the firm's model to factor in the disclosed WAC price of $1,048 per month and an updated launch trajectory.
 
You must log in or register to reply here.
Back
Top